522 related articles for article (PubMed ID: 17323595)
41. [Combination therapy in patients with pulmonary arterial hypertension].
Ewert R; Opitz CF; Schäper C; Gläser S
Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S187-90. PubMed ID: 18814093
[TBL] [Abstract][Full Text] [Related]
42. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
43. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.
Sebkhi A; Strange JW; Phillips SC; Wharton J; Wilkins MR
Circulation; 2003 Jul; 107(25):3230-5. PubMed ID: 12796132
[TBL] [Abstract][Full Text] [Related]
44. Central retinal vein occlusion in a patient after being commenced on sildenafil citrate for pulmonary arterial hypertension.
Pinto LM; Morekar S; Mahashur AA
Indian J Chest Dis Allied Sci; 2009; 51(4):249-51. PubMed ID: 20073379
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.
Watanabe H
Intern Med; 2004 Oct; 43(10):891-3. PubMed ID: 15575233
[No Abstract] [Full Text] [Related]
46. Therapeutic combination of sildenafil and iloprost in a preterm neonate with pulmonary hypertension.
Gürakan B; Kayiran P; Oztürk N; Kayiran SM; Dindar A
Pediatr Pulmonol; 2011 Jun; 46(6):617-20. PubMed ID: 21438177
[TBL] [Abstract][Full Text] [Related]
47. [Bosentan and chronic thromboembolic pulmonary hypertension].
Tomás C; Callejas-Rubio JL; Ríos-Fernández R; Ortego-Centeno N
Med Clin (Barc); 2007 Nov; 129(16):639. PubMed ID: 18001681
[No Abstract] [Full Text] [Related]
48. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
[TBL] [Abstract][Full Text] [Related]
49. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure.
Yin J; Kukucka M; Hoffmann J; Sterner-Kock A; Burhenne J; Haefeli WE; Kuppe H; Kuebler WM
Circ Heart Fail; 2011 Mar; 4(2):198-206. PubMed ID: 21216837
[TBL] [Abstract][Full Text] [Related]
50. Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure.
Stehlik J; Movsesian MA
J Card Fail; 2009 Feb; 15(1):31-4. PubMed ID: 19181291
[TBL] [Abstract][Full Text] [Related]
51. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension.
Noori S; Friedlich P; Wong P; Garingo A; Seri I
Neonatology; 2007; 91(2):92-100. PubMed ID: 17344658
[TBL] [Abstract][Full Text] [Related]
52. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
[TBL] [Abstract][Full Text] [Related]
53. Cardiovascular effects of sildenafil citrate and recommendations for its use.
Kloner RA; Zusman RM
Am J Cardiol; 1999 Sep; 84(5B):11N-17N. PubMed ID: 10503571
[TBL] [Abstract][Full Text] [Related]
54. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].
Jiménez López-Guarch C; Escribano Subias P; Tello de Meneses R; Delgado Jiménez JF; Sadia Pérez D; Velázquez Martín MT; Gómez Sánchez MA; Sáenz de la Calzada C
Rev Esp Cardiol; 2004 Oct; 57(10):946-51. PubMed ID: 15469792
[TBL] [Abstract][Full Text] [Related]
55. Sildenafil citrate therapy for pulmonary arterial hypertension.
Hoeper MM; Welte T
N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16525151
[No Abstract] [Full Text] [Related]
56. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
57. Sildenafil citrate therapy for pulmonary arterial hypertension.
Galiè N; Ghofrani HA; Torbicki A; Barst RJ; Rubin LJ; Badesch D; Fleming T; Parpia T; Burgess G; Branzi A; Grimminger F; Kurzyna M; Simonneau G;
N Engl J Med; 2005 Nov; 353(20):2148-57. PubMed ID: 16291984
[TBL] [Abstract][Full Text] [Related]
58. Sildenafil for pulmonary hypertension in ARDS: a new pleasant effect?
Blanch L; Albaiceta GM
Intensive Care Med; 2010 May; 36(5):729-31. PubMed ID: 20130829
[No Abstract] [Full Text] [Related]
59. Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation.
Lopez-Meseguer M; Berastegui C; Monforte V; Bravo C; Domingo E; Roman A
Transplant Proc; 2013; 45(6):2347-50. PubMed ID: 23953548
[TBL] [Abstract][Full Text] [Related]
60. Sildenafil citrate therapy for pulmonary arterial hypertension.
Izbicki G; Rosengarten D; Picard E
N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16528809
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
